Study Confirms Benefit of Regorafenib in Previously Treated Metastatic Colorectal Cancer
the ONA take:
According to research presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have confirmed that regorafenib is beneficial for the treatment of patients with previously treated metastatic colorectal cancer.
The phase III CORRECT study previously demonstrated a significant improvement in progression-free survival in patients with previously treated metastatic colorectal cancer. For the phase IIIb CONSIGN trial, researchers prospectively assessed the efficacy and safety of regorafenib in patients with pre-treated metastatic colorectal cancer before marketing of the drug was authorized.
The study showed that the estimated progression-free survival was 2.7 months and there were no surprising findings in regard to adverse events.
The CONSIGN trial is significant in that its patient population more closely resembled a real world population of patients compared with the CORRECT trial
"CONSIGN confirms the efficacy and safety data of the randomised phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice," Dirk Arnold, MD, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said.
Researchers have confirmed that regorafenib is effective for the treatment of previously treated metastatic colorectal cancer.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|